Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 7
1947 2
1948 5
1949 1
1950 3
1951 3
1952 5
1953 6
1954 4
1955 4
1956 4
1957 5
1958 5
1959 2
1960 3
1961 5
1962 3
1963 1
1964 5
1965 3
1966 5
1968 1
1969 1
1970 1
1973 1
1974 2
1975 1
1976 3
1977 2
1978 7
1979 17
1980 19
1981 14
1982 17
1983 15
1984 11
1985 13
1986 18
1987 9
1988 4
1989 5
1990 9
1991 7
1992 9
1993 3
1994 10
1995 8
1996 12
1997 13
1998 10
1999 5
2000 10
2001 12
2002 31
2003 12
2004 13
2005 16
2006 17
2007 12
2008 14
2009 15
2010 11
2011 11
2012 10
2013 12
2014 15
2015 12
2016 22
2017 18
2018 21
2019 14
2020 14
2021 8
2022 13
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

647 results

Results by year

Filters applied: . Clear all
Page 1
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA Jr, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Megyesfalvi Z, et al. Among authors: bunn pa jr. CA Cancer J Clin. 2023 Nov-Dec;73(6):620-652. doi: 10.3322/caac.21785. Epub 2023 Jun 17. CA Cancer J Clin. 2023. PMID: 37329269 Free article. Review.
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. Travis WD, et al. Among authors: bunn p. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005. Epub 2020 Jan 28. J Thorac Oncol. 2020. PMID: 32004713 Free PMC article. Review.
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Chaft JE, et al. Among authors: bunn pa. Nat Med. 2022 Oct;28(10):2155-2161. doi: 10.1038/s41591-022-01962-5. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097216 Free PMC article. Clinical Trial.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Hanna N, et al. Among authors: bunn pa jr. J Clin Oncol. 2004 May 1;22(9):1589-97. doi: 10.1200/JCO.2004.08.163. J Clin Oncol. 2004. PMID: 15117980 Corrected and republished. Clinical Trial.
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Kris MG, et al. Among authors: bunn pa. JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741. JAMA. 2014. PMID: 24846037 Free PMC article. Clinical Trial.
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR. Wang Y, et al. Among authors: bunn p. Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542. Ann Oncol. 2019. PMID: 30596880 Free PMC article. Clinical Trial.
Fever.
Dinarello CA, Bunn PA Jr. Dinarello CA, et al. Among authors: bunn pa jr. Semin Oncol. 1997 Jun;24(3):288-98. Semin Oncol. 1997. PMID: 9208885 Review.
2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Schenk EL, Patil T, Pacheco J, Bunn PA Jr. Schenk EL, et al. Among authors: bunn pa jr. Oncologist. 2021 Mar;26(3):e454-e472. doi: 10.1002/onco.13590. Epub 2020 Dec 20. Oncologist. 2021. PMID: 33179378 Free PMC article. Review.
647 results